What this video covers
A video from ARDD, posted on Oct 22, 2026. It is about the science of aging.
It comes from a research institute, foundation or scientific meeting on aging. We link to it; we don't make or endorse it. Research stages on this site come from published studies, not from videos.
From the video's description
Feixiong Cheng, Cleveland Clinic, presents at the 13th Aging Research and Drug Discovery Meeting: AI4Cure-AD Platform for Alzheimer's Disease Drug Development Key takeaways: – Combines human genetics and multi-omics, deep phenotypes, AI target prediction, EHR data and validation in iPSC neurons and organoids. – Single-cell atlas of more than 2,200 individuals and ~40 million nuclei. – AI flagged sildenafil for repurposing; EHR analysis linked it to 30–40% lower Alzheimer’s risk, leading to a Phase 2 trial. – Genetics pointed to EPHB2 as a causal target; editing in human iPSC neurons was neuroprotective and reduced tau hyperphosphorylation. – An EPHB2 inhibitor reduced amyloid and neuroinflammation in mice, completed Phase 1a and is in a ~30-person Phase 1b pilot focused on CSF and plasma biomarkers. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference …
Written by ARDD on YouTube.
More videos like this
Research instituteKejun (Albert) Ying at ARDD2026: An open world model for human health and mortalityThe science of aging
Research instituteHao Pei at ARDD2026: Aging Is Multidimensional — So Must Be the DataThe science of aging
Research instituteYuancheng (Ryan) Lu at ARDD2026: Functional Genomics and Virtual ScreeningThe science of aging
Research instituteCapital Markets and Philanthropy Panel at ARDD2026: What does AI in Longevity Biotech really need?The science of aging